MarginsXMarginsX
Home › Markets › BHST

BioHarvest Sciences Inc. (BHST)

BHST trades on Nasdaq. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.38
-8.31% on the day
Market cap
$31.3M
Nano cap
Revenue · 2025
$34.5M
+37.0% on 2024
Net income · 2025
-$11.1M
-32.3% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 40-F (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1723464/000137647426000257/0001376474-26-000257-index.htm. Net income: SEC 40-F (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerBHST on Nasdaq
SectorThe Nasdaq screener gives no sector
IndustryThe Nasdaq screener gives no industry
CountryCanada
IPO yearNot reported by the screener
SEC CIK0001723464
SEC industry codePharmaceutical Preparations
Incorporated inBC

Financials · 2025

LineValue
Revenue$34.5M
Net income-$11.1M
Operating income-$5.6M
Net margin-32.3%
Operating margin-16.2%
Revenue growth+37.0%
Cash$23.0M
Total assets$47.7M
P/E (computed)Net income was not positive
P/S (computed)0.9×

Warning signs

Cash runway
38.2 months
$23.0M cash at December 31, 2025
Share count, 1 year
+30.8%
2024-12-31 to 2025-12-31
Going-concern doubt
No
40-F filed March 31, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.40-F 2026-03-31
Cash and burn$23.0M cash; operating cash flow -$1.8M a quarter.Report 2025-12-31
Shares outstanding22,666,842 (2025-12-31); 17,327,716 a year earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorZiv Haft Certified Public Accountants (Isr.), Tel Aviv, IsraelPCAOB Form AP 2026-04-15
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
$34.5M-$11.1M-$7.2M$23.0M$149K$34.5M40-F 2026-03-31
FY 2024
2024-12-31
$25.2M-$12.9M-$6.7M$2.4M$3.9M$25.2M40-F 2026-03-31
FY 2023
2023-12-31
$12.7M-$12.6M-$8.5M$5.4M$20.5M$12.7M40-F 2025-03-31

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-3
POS AM2025-12-29
Latest annual report
BIOHARVEST SCIENCES INC. - FORM 40-F SEC FILING
40-F2026-03-31
Latest quarterly / interim
REPORT
6-K2026-11-12

Source: SEC EDGAR submissions feed, 137 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-5.3%
1 month-17.3%
3 months-27.3%
Year to date-71.0%
1 year-79.4%
From 52-week high-79.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers

No industry from the screener, so peers can't be matched.

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier